Jpmorgan Chase & CO Onconova Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$0.57 - $1.0 $2 - $4	4 Added 7.84%	55 $0
Q1 2024 May 10, 2024	BUY	$0.67 - $1.01 $10 - $15	15 Added 41.67%	51 $0
Q4 2023 Feb 12, 2024	BUY	$0.62 - $0.79 $6 - $8	11 Added 44.0%	36 $0
Q3 2023 Nov 14, 2023	BUY	$0.71 - $1.15 $17 - $28	25 New	25 $0
Q2 2022 Aug 11, 2022	SELL	$1.04 - $1.9 $5,005 - $9,144	-4,813 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$1.46 - $2.82 $7,026 - $13,572	4,813 New	4,813 $9,000

249K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.